Guardant Health Inc logo

GH - Guardant Health Inc News Story

$135.39 0.8  0.6%

Last Trade - 07/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £9.80bn
Enterprise Value £9.13bn
Revenue £205.2m
Position in Universe 790th / 6858

BRIEF-Guardant Health Has CE-Marked Guardant360 CDx For Tumor Mutation Profiling In Patients With Any Solid Malignant Neoplasm

Tue 2nd March, 2021 1:05pm
March 2 (Reuters) - Guardant Health  GH.O :
    * GUARDANT HEALTH SAYS HAS CE-MARKED GUARDANT360 CDX FOR
TUMOR
MUTATION PROFILING IN PATIENTS WITH ANY SOLID MALIGNANT NEOPLASM
    * GUARDANT - TEST APPROVED AS COMPANION DIAGNOSTIC TO
IDENTIFY
NON-SMALL CELL LUNG CANCER PATIENTS WITH EGFR ALTERATIONS WHO
MAY BENEFIT FROM TREATMENT WITH TAGRISSO

Source text for Eikon:  ID:nBw3fDlwTa 
Further company coverage:  GH.O 

 ((reuters.briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.